L'intérêt à découvert pour Mira Pharmaceuticals donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Mira Pharmaceuticals. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Mira Pharmaceuticals (NASDAQ:MIRA) Stock, Rapport sur les intérêts à découvert

Mira Pharmaceuticals

Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.

MIRA Pharmaceuticals, Inc. - Common Stock

Mira Pharmaceuticals Inc

MIRAI Corp

MIRAIT One Corp

MIRAMAR RESOURCES LTD by MIRAMAR RESOURCES LTD

MIRATI THERAPEUTICS INC COM

MIRACLE ENTMT INC by Miracle Entertainment Inc.

Miracle Entertainment Inc

MIRAGE ENERGY CORP by Mirage Energy Corporation

Mirage Energy Corp

MIRAMAR HOTE & INVST CO by Miramar Hotel & Investment Co., Ltd.

Miramar Hotel & Investment Co Ltd

TAKARA LEBEN CO LTD by Takara Leben Co., Ltd.

Mirarth Holdings Inc

MIRASOL RESOURCES LTD by Mirasol Resources Ltd.

Mirasol Resources Ltd

Miratap Inc

MIRAVANT MEDICAL TECHS by Miravant Medical Technologies

Miravant Medical Technologies

Loop Capital analyst Gary Mobley maintains ON Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) with a Buy and lowers the price target from $65 to $55.

News

Price Target

Analyst Ratings

Loop Capital Maintains Buy on ON Semiconductor, Lowers Price Target to $55

Loop Capital analyst Gary Mobley maintains Lattice Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSCC#NASDAQ">LSCC</a>) with a Buy and lowers the price target from $85 to $75.

LSCC

Loop Capital Maintains Buy on Lattice Semiconductor, Lowers Price Target to $75

Loop Capital analyst Mark Schappel maintains Palantir Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) with a Buy and raises the price target from $125 to $130.

PLTR

Loop Capital Maintains Buy on Palantir Technologies, Raises Price Target to $130

Ventas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>) has outperformed the market over the past 5 years by 3.96% on an annualized basis producing an average annual return of 17.78%. Currently, Ventas has a market capitalization of $29.69 billion. 
Buying $100 In VTR: If an investor had bought $100 of VTR stock 5 years ago, it would be worth $218.70 today based on a price of $65.83 for VTR at the time of writing.
<h3>Ventas's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746572414_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much You Would Have Made Owning Ventas Stock In The Last 5 Years

Loop Capital analyst Anthony Chukumba maintains Floor &amp; Decor Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FND#NYSE">FND</a>) with a Hold and lowers the price target from $95 to $75.

Loop Capital Maintains Hold on Floor & Decor Hldgs, Lowers Price Target to $75

If you were to ask a veteran investor if there&#8217;s a <a href="https://www.benzinga.com/etfs">100% international equity ETF</a> that&#8217;s up more than 16% year-to-date in 2025, they&#8217;d likely answer with a healthy dose of skepticism and a side of disbelief. 
In an exclusive sit-down with Bancreek Capital CEO Andrew Skatoff, one thing became clear: the idea that international equity ETFs are boring, over-diversified and underperforming is in line for a do-over. Skatoff&#8217;s fund, the Bancreek International Large Cap ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BCIL#NYSE">BCIL</a>), has flipped that narrative. With a number 1 rank out of 1,053 active and passive ETFs in April, according to Bloomberg, BCIL is demonstrating that a concentrated international portfolio can beat bloated benchmarks and old-school incumbents.
Also Read: <a href="https://www.benzinga.com/etfs/specialty-etfs/25/05/45229767/pltr-focused-etfs-down-whats-really-behind-palantirs-plunge-the-numbers-dont-tell-the-full-st">PLTR-Focused ETFs Down: What&#8217;s Really Behind Palantir&#8217;s Plunge? The Numbers Don&#8217;t Tell The Full Story</a>
<h1 class="wp-block-heading">From Niche To Knockout</h1>
This ETF&#8217;s approach is simple yet successful: target international firms with what Bancreek defines as &#8220;institutional endurance&#8221;— companies with durability, resilience, longevity and growth. It isn&#8217;t buzzword stew, it&#8217;s model-based, high-conviction strategy that winnows thousands of developed-market stocks down to the ones that count.
&#8220;At any given time, there may only be 50 such businesses in our investable universe,&#8221; Bancreek Capital Advisors CEO Andrew Skatoff says. &#8220;Through extensive research, we've found that 30 positions strike the right balance between long- term compounding potential and near-term volatility management. Holding significantly more positions in the portfolio dilutes this quality and erodes risk-adjusted returns. That's our edge — precision over breadth.&#8221;
The ETF&#8217;s portfolio is surprisingly evenly weighted. Concentrated, yes, but closer to equal-weight than most passive funds. BCIL&#8217;s top 10 holdings, for example, account for just about 40% of the fund — scarcely more concentrated than the S&amp;P 500, which has 16x as many names but a 36% top-10 weight.
<h1 class="wp-block-heading">Why Go International Now?</h1>
Let's face it: for the past decade, international equities have had little appeal — mildly interesting but quickly discarded. But the tide may be turning.
"The global trade landscape is shifting. U.S. policy decisions are increasingly disrupting long-standing trade flows. If the U.S. turns inward, those opportunities will likely be backfilled by regional champions in countries like Japan, the U.K., Canada, and Australia," Skatoff notes. Add in the valuation gap between U.S. and international markets, and you've got a real opportunity for alpha generation.
International developed markets are still discounted to the U.S., even with recent good performance. And with themes such as supply chain regionalization and geopolitical rebalancing gaining traction, BCIL&#8217;s timing begins to feel more like a strike and less like a contrarian bet.
<h1 class="wp-block-heading">The Quant Edge</h1>
At the center of Bancreek&#8217;s strategy is a proprietary quantitative engine — one that&#8217;s been refined by years of basic research but engineered for speed and scale.
&#8220;These models were built on years of deep fundamental research and have gone through countless iterations to find the right set of variables to help us identify these structurally advantaged businesses,&#8221; Skatoff says. &#8220;Now, our models can do it systematically, with speed and consistency — and we can deliver that efficiency to retail investors through our ETFs.&#8221;
The model focuses on not only the financial health but also the quality of capital deployment, business model robustness, and scalability — metrics that generally translate well internationally.
<h1 class="wp-block-heading">What About Diversification?</h1>
Critics balk at the 30 stocks in this global fund. But BCIL isn&#8217;t quantity, it&#8217;s quality with built-in diversification. One of the holdings, for instance, is a software aggregator that owns over 500 companies — a fund within a fund, of sorts.
&#8220;We believe in outsourcing diversification to the companies themselves — specifically, to world-class management teams with a proven ability to identify and acquire high-quality businesses,&#8221; Skatoff says.
With only 30 names, BCIL has shown less volatility than the FTSE Developed ex-US All Cap Index, which contains over 3,000 stocks, noted Skatoff. Evidence that when it comes to building a portfolio, less can be more — if you choose wisely.
<h1 class="wp-block-heading">BCUS Vs BCIL</h1>
Although BCIL targets established international names, Bancreek also manages a U.S. large-cap strategy, the Bancreek U.S. Large Cap ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BCUS#NYSE">BCUS</a>), based on the same system. 
&#8220;Both ETFs use the same investment engine — the difference lies in the universe: BCUS draws from U.S. large caps, while BCIL focuses exclusively on developed international names,&#8221; said Skatoff.
Though overshadowed by BCIL&#8217;s star turn, BCUS has also beaten the S&amp;P 500 in 2025 and navigated volatility with aplomb, especially in a volatile month like April. Together, they form Bancreek&#8217;s two-engine style of equity investing: same strategy, alternate hunting grounds.
And for now, the results speak louder than any marketing brochure ever could.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/etfs/specialty-etfs/25/05/45197995/exclusive-invest-like-buffett-this-etf-ceo-is-riding-the-berkshire-hathaway-buzz">EXCLUSIVE: &#8216;Invest Like Buffett,&#8217; This ETF CEO Is Riding The Berkshire Hathaway Buzz</a></li>
</ul>
Photo: Gumbariya via Shutterstock

Sector ETFs

Exclusives

ETFs

BCIL

BCUS

EXCLUSIVE: Nobody Believed A 100% International ETF Could Beat 1,000+ Rivals, Until This CEO Proved Them Wrong — His Mantra? 'Precision Over Breadth'

Granite Point Mortgage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPMT#NYSE">GPMT</a>) reported quarterly losses of $(0.57) per share which beat the analyst consensus estimate of $(0.73) by 21.92 percent. This is a 2000 percent decrease over earnings of $0.03 per share from the same period last year. The company reported quarterly sales of $8.04 billion which beat the analyst consensus estimate of $8.86 million by 90.64K percent. This is a 64.10K percent increase over sales of $12.52 million the same period last year.

Earnings

Earnings Beats

GPMT

Granite Point Mortgage Q1 Adj. EPS $(0.57) Beats $(0.73) Estimate, Net interest income $8.04B Beat $8.86M Estimate

Barclays analyst Dan Levy maintains Ford Motor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) with a Equal-Weight and raises the price target from $8 to $9.

Barclays Maintains Equal-Weight on Ford Motor, Raises Price Target to $9

Reinsurance Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RGA#NYSE">RGA</a>) has outperformed the market over the past 5 years by 2.76% on an annualized basis producing an average annual return of 16.59%. Currently, Reinsurance Gr has a market capitalization of $13.10 billion. 
Buying $1000 In RGA: If an investor had bought $1000 of RGA stock 5 years ago, it would be worth $2,085.99 today based on a price of $198.19 for RGA at the time of writing.
<h3>Reinsurance Gr's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746571524_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Reinsurance Gr Stock In The Last 5 Years

DA Davidson analyst Michael Shlisky maintains Standex International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SXI#NYSE">SXI</a>) with a Buy and lowers the price target from $207 to $200.

DA Davidson Maintains Buy on Standex International, Lowers Price Target to $200

Most people would think giving away $60 billion qualifies as the ultimate sacrifice. Warren Buffett disagrees.
While many admire <a href="https://www.benzinga.com/personal-finance/25/04/44889632/warren-buffetts-son-cashed-in-90k-instead-of-waiting-on-500-million-now-hes-using-buffett-bucks-to-build-his-own-dream-town-in-new-york">Buffett for his record-setting philanthropy</a>, the 94-year-old billionaire insists he's given up nothing at all. In fact, he believes those who give their time—not just their money—are the true heroes. And in a rare moment of reflection, he openly admits he hasn't done nearly enough of that.
Don't Miss:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.30/share!</a></li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> this is your last chance to become an investor for $0.80 per share.</a></li>
</ul>
"The easiest deed in the world is to give away money that will never be of any real use to you or your family," Buffett wrote in a 2021 statement accompanying his <a href="https://www.berkshirehathaway.com/donate/jun2321.pdf">annual contribution of Berkshire Hathaway (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>, BRK.B)) shares</a>.&nbsp;
"I've made no sacrifice nor has my family." He credited his fortune not to hard trade-offs or deprivation, but to "compound interest, a long runway, wonderful associates and our incredible country."
Buffett, who pledged to give away more than 99% of his Berkshire Hathaway shares, reached a milestone that year—distributing $4.1 billion, marking the halfway point to this goal. Yet, despite the billions, he acknowledged: "A much more admirable form of philanthropy than mine involves the giving of personal time and effort. I've done little of that."
Instead, Buffett has long admitted he chose what he calls the "wholesale" approach to giving. Large checks, strategic donations, and delegating the hard work to major foundations like the Bill &amp; Melinda Gates Foundation, where he served as an inactive trustee until 2021.&nbsp;
Trending: <a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.
His sister, Doris, took the opposite path. She practiced what Buffett called "retail" philanthropy—personally helping thousands in small, individual ways. "She used both her heart and head to help thousands," Buffett noted after her passing.
The contrast wasn't just philosophical. It was personal. Buffett often credited his first wife, Susan, for urging him to embrace philanthropy in the first place. She advocated for giving while young and connected directly with causes.&nbsp;
Buffett, meanwhile, focused on growing their wealth—driven by his fascination with compounding and a desire to keep full control of Berkshire Hathaway. As he later explained, "I was restrained by the desire to retain unassailable control of Berkshire. It was only after my wife's death that I, at 75, <a href="https://www.benzinga.com/personal-finance/24/04/38020981/warren-buffetts-first-wife-said-he-cared-about-the-win-never-about-money-everybody-can-read-what">stepped on the accelerator</a>."
Still, despite his monumental donations—<a href="https://www.forbes.com/sites/dereksaul/2024/11/25/never-wished-to-create-a-dynasty-warren-buffett-donates-11-billion-in-berkshire-stock-and-updates-will/">Forbes estimates</a> Buffett has given more than $60 billion, likely making him history's largest philanthropist—he remains clear-eyed about what he hasn't given. "Those who give their love and time…are the heroes of philanthropy. They receive no recognition…but they silently make those establishments work smoothly to benefit those who have received the short straws in life," Buffett wrote.
See Also: <a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a>
That humility extends to his family plans as well. His famous advice is to leave your kids "enough to do anything, but not enough to do nothing."
Buffett also revealed in a <a href="https://www.wsj.com/finance/warren-buffett-gives-us-a-preview-of-his-will-419ad46d">Wall Street Journal interview</a> last year that his donations to the Gates Foundation <a href="https://www.benzinga.com/news/management/24/06/39550353/warren-buffett-sets-up-new-trust-as-he-turns-away-from-gates-foundation">will end after his death</a>. "The Gates Foundation has no money coming after my death," he said, noting that his children would instead direct the remainder of his fortune.
While Buffett may downplay his extreme donations and the lives they've touched, there's no denying the impact. And for those without billions to give, time can be just as powerful.
Read Next:
<ul>
<li>Donald Trump just announced a $500 billion AI infrastructure deal — <a href="https://www.benzinga.com/money/seize-a-share-while-you-still-can-in-the-2-trillion-entertainment-market-with-elf-labs-at-just-2-25-share">here's how you can invest in the entertainment market's next big disruptor at $2.25 per share</a>.</li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.30/share!</a></li>
</ul>
Image: Shutterstock

Personal Finance

'I've Made No Sacrifice' — Warren Buffett Has Given Away $60 Billion But Says Giving Time Is More 'Admirable': 'I've Done Little Of That'

DA Davidson analyst Thomas Diffely maintains Ichor Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICHR#NASDAQ">ICHR</a>) with a Buy and lowers the price target from $50 to $45.

ICHR

DA Davidson Maintains Buy on Ichor Holdings, Lowers Price Target to $45

DA Davidson analyst Gil Luria maintains Palantir Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) with a Neutral and raises the price target from $100 to $115.

DA Davidson Maintains Neutral on Palantir Technologies, Raises Price Target to $115

EQT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>) has outperformed the market over the past 20 years by 10.94% on an annualized basis producing an average annual return of 19.14%. Currently, EQT has a market capitalization of $32.00 billion. 
Buying $100 In EQT: If an investor had bought $100 of EQT stock 20 years ago, it would be worth $3,273.07 today based on a price of $53.45 for EQT at the time of writing.
<h3>EQT's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746570620_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning EQT Stock In The Last 20 Years

CIBC analyst Hamir Patel maintains Mercer Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MERC#NASDAQ">MERC</a>) with a Neutral and lowers the price target from $6 to $5.

MERC

CIBC Maintains Neutral on Mercer Intl, Lowers Price Target to $5

VTEX

CORRECTION: Vtex Q1 EPS $0.005 Beats $(0.01) Estimate, Sales $54.16M Beat $52.88M Estimate

Macquarie analyst Ross Compton maintains Maplebear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CART#NASDAQ">CART</a>) with a Outperform and maintains $55 price target.

CART

Macquarie Maintains Outperform on Maplebear, Maintains $55 Price Target

Mastercard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) has outperformed the market over the past 10 years by 9.44% on an annualized basis producing an average annual return of 19.72%. Currently, Mastercard has a market capitalization of $507.65 billion. 
Buying $100 In MA: If an investor had bought $100 of MA stock 10 years ago, it would be worth $604.18 today based on a price of $558.98 for MA at the time of writing.
<h3>Mastercard's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746569718_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Mastercard 10 Years Ago Would Be Worth Today

Macquarie analyst Chad Beynon maintains Playa Hotels &amp; Resorts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLYA#NASDAQ">PLYA</a>) with a Neutral and maintains $13.5 price target.

PLYA

Macquarie Maintains Neutral on Playa Hotels & Resorts, Maintains $13.5 Price Target

Flywire (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLYW#NASDAQ">FLYW</a>) reported quarterly earnings of $0.03 per share. This is a 160 percent increase over losses of $(0.05) per share from the same period last year. The company reported quarterly sales of $133.45 million which beat the analyst consensus estimate of $123.74 million by 7.85 percent. This is a 16.96 percent increase over sales of $114.10 million the same period last year.

FLYW

CORRECTION: Flywire Q1 Adj. EPS $0.03 Up From $(0.05) YoY, Sales $133.45M Beat $123.74M Estimate

Press Releases

MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site

MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End

MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development

MIRA Pharmaceuticals Announces Approval and Initiation of Phase 1 Clinical Trial for Ketamir-2 in Neuropathic Pain

MIRA Pharmaceuticals Expands Ketamir-2 Development with Topical Treatment for Localized Neuropathic and Inflammatory Pain

MIRA Pharmaceuticals Signs Binding Letter of Intent to Acquire SKNY Pharmaceuticals, Securing a $5 Million Capital Infusion to Advance Weight Loss and Smoking Cessation Drug Development

MIRA Pharmaceuticals Enrolls First Subjects in Phase 1 Clinical Trial of Ketamir-2 for Neuropathic Pain

MIRA Pharmaceuticals Announces Positive Results for Ketamir-2 in Diabetic Neuropathy Animal Model, Reinforcing Confidence Ahead of Phase I Completion

MIRA Pharmaceuticals Reports Positive In Vitro Drug Release Data for Topical Ketamir-2, Targeting $11B+ U.S. Topical Pain Relief Market and Exploring FDA Fast Track Designation

MIRA Pharmaceuticals Reports No Brain Toxicity in FDA-Required Study of Ketamir-2, Confirming Absence of Ketamine-Linked Neurotoxicity

MIRA

Addex Therapeutics Ltd - American Depositary Shares

Addex Therapeutics

Aspire Biopharma Holdings, Inc. - Common Stock

Aspire Biopharma Hldgs

Athira Pharma

CalciMedica

Cognition Therapeutics, Inc. - Common Stock

Cognition Therapeutics

Cingulate

Cocrystal Pharma

Cadrenal Therapeutics, Inc. - Common Stock

Cadrenal Therapeutics

Dare Bioscience

Durect

Gelteq

Hoth Therapeutics

IGC Pharma

Jupiter Neurosciences, Inc. - Common Stock

Jupiter Neurosciences

Kiora Pharmaceuticals, Inc. - Common Stock

Kiora Pharmaceuticals

Lexaria Bioscience

Lipocine

NRX Pharmaceuticals

Pulmatrix

Relmada Therapeutics, Inc. - Common Stock

Relmada Therapeutics

Scilex Holding

China SXT Pharmaceuticals, Inc. - Common Stock

China SXT Pharmaceuticals

Talphera

TherapeuticsMD

VYNE Therapeutics

Rodman & Renshaw

Ascendiant Capital

Screenshot 2024-10-02 at 5.44.40 PM

Biotech

General

Breakthrough Therapies And Novel Treatments - This Biopharma Is Out To Change The Game

Screenshot 2024-09-18 at 6.27.57 PM

MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing On Early Clinical Efficacy Demonstration For Neuropathic Pain In 2025

Screenshot 2024-09-04 at 6.19.41 PM

TELO

Telomir Pharmaceuticals (NASDAQ: TELO) Featured In Local ABC Exclusive Showing Positive Outcomes Of Proposed Age Reversal Pill In Dogs

Screenshot 2024-08-26 at 4.53.37 PM

The Potential Of Ketamir-2: A Safer Treatment For Mental Health Disorders And Neuropathic Pain, IND Filing Expected By Year-End

Screenshot 2024-07-25 at 6.08.16 PM

MIRA Pharmaceuticals (NASDAQ: MIRA) Reports Promising Pre-Clinical Trial Results For Mental Health Treatment, To Submit Investigational New Drug Application By End Of Year

Comments

Mira Pharmaceuticals

Intérêt court

Mira Pharmaceuticals (NASDAQ:MIRA) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL